Aeterna Zentaris Inc. AEZS.TO Stock
Aeterna Zentaris Inc. Price Chart
Aeterna Zentaris Inc. AEZS.TO Financial and Trading Overview
Aeterna Zentaris Inc. stock price | 2.79 CAD |
Previous Close | 3.73 CAD |
Open | 3.68 CAD |
Bid | 3.63 CAD x 0 |
Ask | 3.75 CAD x 0 |
Day's Range | 3.68 - 3.69 CAD |
52 Week Range | 3.18 - 11.25 CAD |
Volume | 1.2K CAD |
Avg. Volume | 1.44K CAD |
Market Cap | 17.87M CAD |
Beta (5Y Monthly) | 1.70707 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -4.67 CAD |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | August 11, 1999 |
1y Target Est | N/A |
AEZS.TO Valuation Measures
Enterprise Value | -28189024 CAD |
Trailing P/E | N/A |
Forward P/E | -1.013774 |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 2.8586848 |
Price/Book (mrq) | 0.5725844 |
Enterprise Value/Revenue | -4.51 |
Enterprise Value/EBITDA | 1.683 |
Trading Information
Aeterna Zentaris Inc. Stock Price History
Beta (5Y Monthly) | 1.70707 |
52-Week Change | -36.00000000000000000000000000000000% |
S&P500 52-Week Change | 20.43% |
52 Week High | 11.25 CAD |
52 Week Low | 3.18 CAD |
50-Day Moving Average | 3.9 CAD |
200-Day Moving Average | 4.65 CAD |
AEZS.TO Share Statistics
Avg. Volume (3 month) | 1.44K CAD |
Avg. Daily Volume (10-Days) | 1.05K CAD |
Shares Outstanding | 4.86M |
Float | 4.85M |
Short Ratio | 3.52 |
% Held by Insiders | 0.45% |
% Held by Institutions | 0.72% |
Shares Short | 1.44K |
Short % of Float | 0.029% |
Short % of Shares Outstanding | 0.029% |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor | 1:25 |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 0% |
Operating Margin (ttm) | -268.29% |
Gross Margin | 98.48% |
EBITDA Margin | -267.97% |
Management Effectiveness
Return on Assets (ttm) | -16.42% |
Return on Equity (ttm) | -57.70% |
Income Statement
Revenue (ttm) | 6.25M CAD |
Revenue Per Share (ttm) | 1.29 CAD |
Quarterly Revenue Growth (yoy) | 40.30% |
Gross Profit (ttm) | N/A |
EBITDA | -16751000 CAD |
Net Income Avi to Common (ttm) | -24342000 CAD |
Diluted EPS (ttm) | -6.5 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 46.56M CAD |
Total Cash Per Share (mrq) | 9.59 CAD |
Total Debt (mrq) | 210K CAD |
Total Debt/Equity (mrq) | 0.67 CAD |
Current Ratio (mrq) | 7.881 |
Book Value Per Share (mrq) | 6.427 |
Cash Flow Statement
Operating Cash Flow (ttm) | -16280000 CAD |
Levered Free Cash Flow (ttm) | -9688375 CAD |
Profile of Aeterna Zentaris Inc.
Country | Canada |
State | SC |
City | Summerville |
Address | 315 Sigma Drive |
ZIP | 29486 |
Phone | (843) 900-3223 |
Website | https://www.zentaris.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | N/A |
Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications; and AEZS-150, a delayed clearance parathyroid hormonefusion polypeptide that is in preclinical trail for the treatment of hypoparathyroidism in adults. Aeterna Zentaris Inc. has a license agreement with University of Wuerzburg to research, develop, manufacture, and sell a potential COVID-19 vaccine; development, manufacture, and commercialization of the treatment for neuromyelitis optica spectrum disorder; and for pre-clinical development towards the potential treatment of Parkinson's disease. It also has a license agreement with Consilient Health Ltd. and NK MEDITECH Ltd. for the development and commercialization of macimorelin in the Republic of Korea; a distribution and commercialization agreement with Er-Kim Pharmaceuticals Bulgaria EOOD for the commercialization of macimorelin for the diagnosis of growth hormone deficiency in children and adults in Turkey and some non-European Union Balkan countries; as well as The University of Sheffield, the United Kingdom for the research, development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of primary hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Summerville, South Carolina.
Q&A For Aeterna Zentaris Inc. Stock
What is a current AEZS.TO stock price?
Aeterna Zentaris Inc. AEZS.TO stock price today per share is 2.79 CAD.
How to purchase Aeterna Zentaris Inc. stock?
You can buy AEZS.TO shares on the Toronto exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Aeterna Zentaris Inc.?
The stock symbol or ticker of Aeterna Zentaris Inc. is AEZS.TO.
Which industry does the Aeterna Zentaris Inc. company belong to?
The Aeterna Zentaris Inc. industry is Biotechnology.
How many shares does Aeterna Zentaris Inc. have in circulation?
The max supply of Aeterna Zentaris Inc. shares is 4.86M.
What is Aeterna Zentaris Inc. Price to Earnings Ratio (PE Ratio)?
Aeterna Zentaris Inc. PE Ratio is now.
What was Aeterna Zentaris Inc. earnings per share over the trailing 12 months (TTM)?
Aeterna Zentaris Inc. EPS is -4.67 CAD over the trailing 12 months.
Which sector does the Aeterna Zentaris Inc. company belong to?
The Aeterna Zentaris Inc. sector is Healthcare.